

CO-ORGANIZED BY




FONDAZIONE  
INTERNAZIONALE  
MENARINI



LIVE

&



ONLINE

# International Symposium on NEW BIOLOGICAL INSIGHTS AND NOVEL DRUGS IN **ACUTE LEUKEMIA**



October 12<sup>th</sup> -13<sup>th</sup> 2021 - Venue: Hotel Monaco Grand Canal, Venice (Italy)

## **UNDER THE PATRONAGE OF:**



## **PRESIDENTS OF THE MEETING:**

**Francesco Lanza**

Section of Hematology & Romagna Metropolitan Transplant Network  
Hospital of Ravenna, Ravenna (Italy)

**Giovanni Martinelli**

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)  
Meldola - FC (Italy)

## **SCIENTIFIC SECRETARIAT:**

**Enrico Maffini**

Section of Hematology & Romagna Metropolitan Transplant Network  
Hospital of Ravenna, Ravenna (Italy)

**Michela Rondoni**

Section of Hematology & Romagna Metropolitan Transplant Network  
Hospital of Ravenna, Ravenna (Italy)

## **CO-ORGANIZED BY:**

**Section of Hematology & Romagna Metropolitan Transplant Network**  
**Hospital of Ravenna**, Ravenna (Italy)

**Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)**  
Meldola - FC (Italy)

**AND**

**FONDAZIONE INTERNAZIONALE MENARINI**

Centro Direzionale Milanofiori

I-20089 Rozzano (Milan, Italy) Edificio L – Strada 6

Phone: +39 02 55308110 | Fax: +39 02 55305739

E-mail: [milan@fondazione-menarini.it](mailto:milan@fondazione-menarini.it) | Website: [www.fondazione-menarini.it](http://www.fondazione-menarini.it)

# PRELIMINARY PROGRAMME

TUESDAY, OCTOBER 12<sup>TH</sup> 2021

08.00 a.m. 08.30 a.m.	Registration of participants
08.30 a.m. 08.40 a.m.	<b>F. Lanza</b> (Ravenna, IT), <b>G. Martinelli</b> (Meldola - FC, IT) Introduction

## SESSION I - GENETIC AND PROGNOSIS IN AML

Chairpersons:	<b>F. Lanza</b> (Ravenna, IT) <b>G. Martinelli</b> (Meldola - FC, IT)
08.40 a.m. 09.00 a.m.	<b>B. Falini</b> (Perugia, IT) Genetic landscape of AML and its relevance for treatment
09.00 a.m. 09.20 a.m.	<b>D. Rondelli</b> (Chicago, IL, USA) DNA repair inhibitors: a possible role in myeloid malignancies
09.20 a.m. 09.40 a.m.	<b>G. Martinelli</b> (Meldola - FC, IT) Mechanism of resistance
09.40 a.m. 10.00 a.m.	General Discussion
10.00 a.m. 10.20 a.m.	Coffee Break

## SESSION II - HIGH RISK LEUKEMIA

Chairpersons:	<b>T. M. Kadia</b> (Houston, TX, USA) <b>A. Nagler</b> (Tel Hashomer, IL)
10.20 a.m. 11.40 a.m.	<b>A. Nagler</b> (Tel Hashomer, IL) Secondary AML
10.40 a.m. 11.00 a.m.	<b>F. Ferrara</b> (Naples, IT) Induction and Consolidation Therapy of high risk Leukemia
11.00 a.m. 11.20 a.m.	<b>T. M. Kadia</b> (Houston, TX, USA) Strategy to overcome resistance of emerging agents
11.20 a.m. 11.40 a.m.	<b>E. Angelucci</b> (Genoa, IT) Allogeneic SCT for High Risk leukemia: when and how
11.40 p.m. 12.00 p.m.	General Discussion
12.00 p.m. 01.00 p.m.	Lunch

### SESSION III - TARGETED THERAPY OF ACUTE LEUKEMIA

Chairpersons:	<b>G. Bug</b> (Frankfurt, DE) <b>B. Savani</b> (Nashville, TN, USA)
01.00 p.m. 01.20 p.m.	<b>D. Niederwisier</b> (Leipzig, DE) Targeting Apoptosis in AML - venetoclax
01.20 p.m. 01.40 p.m.	<b>G. Marconi</b> (Meldola, FC, IT) Midostaurine and new FLT3 inhibitors
01.40 p.m. 02.00 p.m.	<b>J. Cortés</b> (Augusta, GA, USA) IDH1 and IDH2 inhibitors
02.00 p.m. 02.20 p.m.	<b>B. Savani</b> (Nashville, TN, USA) Car-T
02.20 p.m. 02.40 p.m.	General Discussion

### SESSION IV - NEXT GENERATION THERAPY FOR ACUTE LEUKEMIA

Chairpersons:	<b>E. Angelucci</b> (Genoa, IT) <b>TBD</b>
03.00 p.m. 03.20 p.m.	<b>T. M. Kadia</b> (Houston, TX, USA) Targeting MDM2 as a new treatment approach in AML
03.00 p.m. 03.20 p.m.	<b>M. Topp</b> (Wuerzburg, DE) T-Cell engaging Immunotherapy
03.20 p.m. 03.40 p.m.	<b>M. Subklewe</b> (Munich, DE) Bispecific antibody construct for the treatment of AML
03.40 p.m. 04.00 p.m.	<b>A. Venditti</b> (Rome, IT) Hedgehog inhibitors
04.00 p.m. 04.20 p.m.	<b>N. Daver</b> (Houston, TX, USA) Immune based approaches in AML
04.20 p.m. 04.40 p.m.	General Discussion
04.40 p.m. 05.00 p.m.	Coffee Break

## SESSION V - RELEVANCE OF MRD IN AML

Chairperson:	<b>A. Venditti</b> (Rome, IT)
05.00 p.m. 05.20 p.m.	<b>N. Russell</b> (London, UK) Clinical impact of MRD monitoring
05.20 p.m. 05.40 p.m.	<b>F. Buccisano</b> (Rome, IT) Flow cytometry monitoring
05.40 p.m. 06.00 p.m.	<b>P. Valk</b> (Rotterdam, NL) MRD by NGS
06.00 p.m. 06.20 p.m.	<b>E. Estey</b> (Seattle, WA, USA) MRD before and after transplantation
06.20 p.m. 06.40 p.m.	General Discussion
06.40 p.m.	Conclusion of the 1 <sup>st</sup> day

## WEDNESDAY, OCTOBER 13<sup>TH</sup> 2021

### SESSION VI - RARE LEUKEMIAS

Chairperson:	<b>L. Kumar</b> (New Delhi, IN)
09.00 a.m. 09.20 a.m.	<b>M. Rondoni</b> (Ravenna, IT) Mast cell leukemia
09.20 a.m. 09.40 a.m.	<b>L. Pagano</b> (Rome, IT) Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
09.40 a.m. 10.00 a.m.	Discussion

### SESSION VII - NEW TOOLS IN ACUTE LEUKEMIA

Chairperson:	<b>L. Kumar</b> (New Delhi, IN)
10.00 a.m. 10.20 a.m.	<b>A. Madrigal</b> (London, UK) HLA-typing in 2020: relevance in allogeneic HSCT
10.20 a.m. 10.40 a.m.	<b>M. Bocchi</b> (Bologna, IT) Can we predict in vitro the clinical activity of cytostatic drugs: new pharmacogenomic insights
10.40 a.m. 11.00 a.m.	<b>M. De Lima</b> (Cleveland, OH, USA) Haploidentical transplantation in AML
11.00 a.m. 11.20 a.m.	General Discussion
11.20 a.m. 11.40 a.m.	Coffee Break

### SESSION VIII - ACUTE LYMPHOBLASTIC LEUKEMIA (PH NEGATIVE)

Chairpersons:	<b>M. Krampera</b> (Verona, IT) <b>C. Cerchione</b> (Meldola – FC, IT)
11.40 a.m. 12.00 p.m.	<b>E.J. Jabbour</b> (Houston, TX, USA) First line therapy and overall approach
12.00 p.m. 12.20 p.m.	<b>F. Lanza</b> (Ravenna, IT) Role of immunotherapy in refractory-resistant ALL
12.20 p.m. 12.40 p.m.	<b>I. Iacobucci</b> (Memphis, TN, USA) Ph Like leukemia
12.40 p.m. 01.00 p.m.	<b>A. Spyridonidis</b> (Rio-Patras, GR) Transplant in Ph-
01.00 p.m. 01.20 p.m.	General Discussion
01.20 p.m. 02.20 p.m.	Lunch

### SESSION IX - PH+ACUTE LYMPHOBLASTIC LEUKEMIA

Chairpersons:	<b>S. Giebel</b> (Gliwice, PL) <b>M. Krampera</b> (Verona, IT)
02.20 p.m. 02.40 p.m.	<b>S. Soverini</b> (Bologna, IT) Ph+ leukemia: biology and resistance
02.40 p.m. 03.00 p.m.	<b>A. Rambaldi</b> (Bergamo, IT) Treatment of Ph+ALL in young and elderly
03.00 p.m. 03.20 p.m.	<b>S. Giebel</b> (Gliwice, PL) Transplant in Ph+
03.20 p.m. 03.40 p.m.	General Discussion
03.40 p.m. 04.00 p.m.	<b>F. Lanza</b> (Ravenna, IT), <b>G. Martinelli</b> (Meldola - FC, IT) Conclusion of the Symposium
03.40 p.m. 04.20 p.m.	Conclusion of the 2 <sup>nd</sup> day

## FACULTY

### **Emanuele Angelucci**

Hematology and Transplant Program Chair  
IRCCS Ospedale Policlinico San Martino  
Genoa, Italy

### **Massimo Bocchi**

Cellply s.r.l.  
Bologna, IT

### **Francesco Buccisano**

Department of Biomedicine and Prevention  
University Tor Vergata  
Rome, IT

### **Gesine Bug**

Dept of Medicine 2, Hematology and Oncology  
Goethe University Hospital  
Frankfurt, DE

### **Claudio Cerchione**

Hematology Unit  
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS  
Meldola - FC, IT

### **Jorge Cortés**

Georgia Cancer Center  
Medical College of Georgia  
Augusta University  
Augusta - GA, USA

### **Naval Daver**

Department of Leukemia  
MD Anderson Cancer Center  
Houston, TX, USA

### **Marcos J. De Lima**

University Hospitals of Cleveland and Case Western Reserve University  
Cleveland - OH, USA



**Elihu Estey**

AML Clinical Research  
University of Washington  
Fred Hutchinson Cancer Research Center  
Seattle - WA, USA

**Brunangelo Falini**

Department of Medicine Section of Hematology and Clinical Immunology  
Perugia University  
Perugia, IT

**Felicitto Ferrara**

Hematology Division  
Antonio Cardarelli Hospital  
Naples, IT

**Sebastian Giebel**

Dept. of Bone Marrow Transplantation and Onco-Hematology  
Clinical Matters of Maria Sklodowska-Curie National Research Institute of Oncology  
Gliwice, PL

**Ilaria Iacobucci**

Department of Pathology  
St. Jude Children's Research Hospital  
Memphis - TN, USA

**Elias J. Jabbour**

Department of Leukemia, Division of Cancer Medicine  
Anderson Cancer Center  
Houston - TX, USA

**Tapan M. Kadia**

University of Texas  
Anderson Cancer Center  
Houston - TX, USA

**Mauro Krampera**

Hematology Section and Bone Marrow Transplant Unit  
Department of Medicine - University Hospital of Verona  
Verona, IT

**Lalit Kumar**

Medical Oncology  
All India Institute of Medical Sciences  
New Delhi, IN

**Francesco Lanza**

Section of Hematology & Romagna Metropolitan Transplant Network  
Hospital of Ravenna  
Ravenna, IT

**Alejandro Madrigal**

Haematology, UCL Cancer Institute  
Royal Free NHS Trust  
UCL Country Ambassador for México  
London, UK

**Giovanni Marconi**

Hematology Unit  
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS  
Meldola, FC, IT

**Giovanni Martinelli**

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)  
Meldola - FC, IT

**Arnon Nagler**

Hemato-oncology Center and CBB  
Chaim Sheba Medical Center  
Tel Hashomer, IL

**Dietger Niederwiesier**

Hematology and Oncology  
University of Leipzig  
Leipzig, DE

**Livio Pagano**

UOSD Ematologia Geriatrica ed Emopatie Rare  
Policlinico Universitario Agostino Gemelli - IRCCS  
Università Cattolica del Sacro Cuore  
Rome, IT

**Alessandro Rambaldi**

Hematology, University of Milan  
Hematology and Bone Marrow Transplant Unit  
ASST Papa Giovanni XXIII  
Bergamo, IT

**Damiano Rondelli**

Division of Hematology/Oncology  
University of Illinois at Chicago  
Chicago - IL, USA

**Michela Rondoni**

Section of Hematology & Romagna Metropolitan Transplant Network  
Hospital of Ravenna  
Ravenna, IT

**Nigel Russell**

Guy's Hospital  
London, UK

**Bipin Savani**

Vanderbilt University Medical Center  
Nashville - TN, USA

**Simona Soverini**

Dept. of Experimental, Diagnostic and Specialty Medicine  
Hematology/Oncology "Lorenzo e Ariosto Seragnoli"  
University of Bologna  
Bologna, IT

**Alexandros Spyridonidis**

Bone Marrow Transplantation Unit  
Donor Center CBMDP and Institute of Cellular Therapy  
University of Patras  
Rio-Patras, GR

**Marion Subklewe**

Immunotherapy in Hematology,  
LMU University Hospital  
Munich, DE

**Max Topp**

Wuerzburg University  
Wuerzburg, DE

**Peter J.M. Valk**

Hemato-Oncology Laboratory (cytology and molecular diagnostics)  
Dept of Hematology at Erasmus University Medical Center  
Rotterdam, NL

**Adriano Venditti**

Department of Biomedicine and Prevention  
University Tor Vergata  
Rome, IT

## GENERAL INFORMATION

### SECRETARIAT DURING THE MEETING

The Secretariat will be open at the following times:

Tuesday, October 12<sup>th</sup> 2021 from 08.00 a.m. to 07.00 p.m.

Wednesday, October 13<sup>th</sup> 2021 from 08.30 a.m. to 05.00 p.m.

### OFFICIAL LANGUAGE

The official language of the Meeting will be English.

### REGISTRATION

**Direct link here:**

<https://www.fondazione-menarini.it/Home/Eventi/International-Symposium-On-New-Biological-Insights-And-Novel-Drugs-In-Acute-Leukemia/737/Programma>

The meeting is free to attend.

For more information and to register please visit the following website:

[www.fondazione-menarini.it](http://www.fondazione-menarini.it)

### TECHNICAL FACILITIES

Facilities will be available for computer presentations and overhead projections.

A business center with PC (Powerpoint for Windows) will be available for check and preview of presentations. It is essential that speakers take their presentation to the business center at least one hour before the session starts.

The slide center will be open at the following times:

Tuesday, October 12<sup>th</sup> 2021 from 08.00 a.m. to 07.00 p.m.

Wednesday, October 13<sup>th</sup> 2021 from 08.30 a.m. to 05.00 p.m.

### LUNCHES AND COFFEE BREAKS

Lunches and coffee breaks will be served in the Meeting area.

**For more information, please visit the following link or scan the QR Code**

<https://www.fondazione-menarini.it/Home/Eventi/International-Symposium-On-New-Biological-Insights-And-Novel-Drugs-In-Acute-Leukemia/737/Presentazione>



CO-ORGANIZED BY




FONDAZIONE  
INTERNAZIONALE  
MENARINI



LIVE

&



ONLINE

# International Symposium on NEW BIOLOGICAL INSIGHTS AND NOVEL DRUGS IN **ACUTE LEUKEMIA**



Scan the QR code and  
immediately download  
the new APP.



Fondazione  
Internazionale Menarini  
is also on [LinkedIn](#)